Melanoma Research Program Idea Award

The DoD Melanoma Research Program Idea Award is a federal discretionary funding opportunity administered by the U.S. Department of Defense through the Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), under the Congressionally Directed Medical Research Programs (CDMRP). The funding opportunity is associated with Assistance Listing 12.420, Military Medical Research and Development, and is intended to support innovative scientific and medical research focused on melanoma. The FY26 Melanoma Research Program Idea Award is designed specifically to encourage exploratory, high-risk, potentially high-reward projects that may challenge existing paradigms or create entirely new approaches within melanoma research. The program emphasizes innovation and novelty as core evaluation criteria and seeks to generate proof-of-principle findings and preliminary outcomes capable of supporting future follow-on funding applications. The opportunity is forecasted on Grants.gov with an estimated posting date of June 1, 2026, and an estimated application due date of October 14, 2026. Awards are anticipated to be made by September 30, 2027, with project performance expected to begin on the same date. The maximum period of performance for funded projects is two years. The funding announcement states that approximately $5.6 million in total program funding is expected to support approximately 10 awards, with each award capped at approximately $560,000 in total costs. Funding for this opportunity is expected to come from FY26 appropriations, which remain available for use through September 30, 2032. Awards supported through this funding mechanism must be issued no later than September 30, 2027. A defining feature of the Idea Award mechanism is its strong emphasis on innovation and early-stage concepts. The funding announcement specifically notes that preliminary data are discouraged, signaling that applicants are not expected to demonstrate extensive prior proof of feasibility before applying. Instead, reviewers are expected to evaluate the novelty, scientific rationale, and transformative potential of the proposed work. The funding opportunity seeks to support projects capable of opening entirely new lines of investigation or introducing unconventional methodologies, technologies, or conceptual frameworks to melanoma research. The anticipated outcome at the conclusion of the award period is the establishment of foundational evidence and proof of principle that can support subsequent larger-scale research efforts or external funding proposals. The submission process includes a mandatory pre-application stage. Investigators are required to submit a pre-application before they may proceed to a full application. The announcement specifies that investigators must receive an invitation to submit a full application after the pre-application review process. This creates a gated, two-step application structure in which only selected applicants advance to the final proposal stage. While the forecast notice does not specify the exact type of pre-application mechanism, the language indicates a formal invitation-only advancement process. Applicants should expect that additional details regarding required forms, proposal components, evaluation criteria, submission systems, and administrative requirements will become available once the full funding opportunity announcement is officially posted by CDMRP and USAMRAA. Eligibility for the program is listed as unrestricted, meaning the opportunity is open to all applicant entity types subject to any clarifications contained in future full announcement materials. Because the notice states that the opportunity is unrestricted and open to any eligible entity type, the funding opportunity may include nonprofit organizations, institutions of higher education, for-profit entities, small businesses, government organizations, and potentially individual investigators operating through eligible institutions. No cost sharing or matching requirement is associated with this funding opportunity. The forecast announcement explicitly identifies that cost sharing is not required, reducing institutional financial burden for applicants and enabling broader participation from organizations with varying levels of research infrastructure and financial capacity. The funding opportunity is national in scope and does not contain state-based geographic restrictions. The opportunity is therefore considered nationwide and open across all U.S. states and territories. Administrative and applicant support is provided through the eBRAP Help Desk, which serves as the primary contact resource for technical and application assistance. The help desk can be reached by telephone at 301-682-5507 or by email at help@eBRAP.org. Additional program details are expected to be released through the official CDMRP melanoma program webpage referenced in the announcement. Because this is a forecasted opportunity rather than a finalized solicitation, applicants should monitor the official program page and Grants.gov posting for updated guidance, application instructions, review criteria, and any future amendments or deadlines associated with the FY26 Melanoma Research Program Idea Award.

Emphasize highly innovative and exploratory melanoma research concepts; preliminary data are discouraged; proposals should focus on high-risk high-reward approaches capable of establishing proof of principle and generating preliminary findings for future funding opportunities